TY - JOUR T1 - Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung JF - In Vivo JO - In Vivo SP - 1439 LP - 1443 DO - 10.21873/invivo.11926 VL - 34 IS - 3 AU - SHINICHIRO OKAUCHI AU - YUIKA SASATANI AU - TOSHIHIRO SHIOZAWA AU - HIDEYASU YAMADA AU - KUNIHIKO MIYAZAKI AU - NORIO TAKAYASHIKI AU - HIROAKI SATOH Y1 - 2020/05/01 UR - http://iv.iiarjournals.org/content/34/3/1439.abstract N2 - Background/Aim: Pleomorphic carcinoma of the lung is a rare, highly malignant subtype of lung cancer, with a more aggressive clinical course compared with other types of non-small-cell lung cancer (NSCLC). Platinum-containing chemotherapy has been the standard therapy for patients with NSCLC and pembrolizumab is one of the novel and reliable agents for these patients. Case Report: We herein report the case of a 60-year-old man with advanced chemo-naïve pleomorphic carcinoma of the lung who was successfully treated with a combination of pembrolizumab with platinum-containing chemotherapy. Conclusion: In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, our case demonstrates the potential utility of the combination of pembrolizumab with platinum-containing chemotherapy. Our result also suggest that this combination of therapy may be key to the treatment of pleomorphic carcinoma of the lung. ER -